From Conversation to Care

Target Audience

This activity is intended for US-based sexual health, infectious disease, and HIV specialists, as well as other new and established preexposure prophylaxis (PrEP)-prescribing primary care and internal medicine clinicians.

Program Overview

Despite substantial advances in HIV prevention, many individuals who could benefit from pre-exposure prophylaxis (PrEP) remain underserved due to barriers such as limited awareness of HIV risk, stigma, provider uncertainty, and challenges associated with navigating an expanding range of PrEP options. As long-acting injectable (LAI) PrEP becomes increasingly integrated into clinical practice, clinicians must be prepared to engage diverse patient populations, individualize regimen selection, and implement evidence-based protocols for PrEP initiation, monitoring, and follow-up.

This interactive AliveSim™ virtual practice activity immerses learners in realistic patient scenarios that reflect common challenges encountered in HIV prevention care. Through three case-based simulations, participants will practice engaging patients in nonstigmatizing sexual health discussions, identifying appropriate candidates for PrEP, selecting between oral and LAI regimens based on patient preferences and clinical considerations, managing regimen transitions, and addressing adherence and follow-up needs.

By combining advanced simulation technology with expert clinical coaching, AliveSim™ recreates the experience of guided clinical decision-making in a safe, supportive learning environment.

Educational Objectives

After completing this activity, the participant should be better able to:

• Tailor sexual health discussions to engage patients who could benefit from PrEP

• Review guideline recommendations for PrEP initiation, monitoring, and follow-up care

• Select PrEP regimens based on clinical evidence, guidelines, and patient characteristics and preferences

• Manage switching PrEP regimens following current guidelines and recommendations

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Shauna Applin, A-NP, AAHIVs: Consulting Fees: Gilead Sciences, Inc.; Advisor/Advisory Board, Speaker: Gilead Sciences, Inc., Merck; Contracted Research: Gilead Sciences, Inc.

Charlotte-Paige Rolle, MD, MPH: Consulting Fees: Gilead Sciences, Inc., Theratechnologies, Inc., ViiV Healthcare; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g. speakers’ bureaus): Gilead Sciences, Inc., ViiV Healthcare Company; Contracted Research: Gilead Sciences, Inc., MSD, ViiV Healthcare Company

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.